Edition:
United Kingdom

OncoTherapy Science Inc (4564.T)

4564.T on Tokyo Stock Exchange

246JPY
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
¥246
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
801,029
52-wk High
¥311
52-wk Low
¥220

Latest Key Developments (Source: Significant Developments)

OncoTherapy Science receives patent in Japan
Thursday, 13 Jul 2017 

July 13 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it received a patent (No.6159948 )for MELK specific inhibitors in Japan.  Full Article

OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167
Friday, 15 Jul 2016 

OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.  Full Article

OncoTherapy Science gets patent license
Monday, 16 May 2016 

OncoTherapy Science Inc <4564.T>: Says received a patent license in China .Says the patent is for specific inhibitor of TOPK (T-LAK cell-originated protein kinase), which being developed as an anti-cancer agent.  Full Article

OncoTherapy Science announces trial result of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma
Tuesday, 22 Mar 2016 

OncoTherapy Science Inc:Announces the positive results of the primary objectives which were safety and bio-distribution were confirmed from Phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma conducted in France.  Full Article

OncoTherapy Science announces positive trial result of phase I/II clinical study of OTSGC-A24
Tuesday, 22 Mar 2016 

OncoTherapy Science Inc:Announces positive trial result of phase I/II clinical study of carcinoma peptide vaccine cocktail OTSGC-A24 for the treatment of gastric cancer, in Singapore, Korea and Japan.  Full Article

OncoTherapy Science announces positive trial result of phase I clinical study of MELK inhibitor OTS167
Wednesday, 16 Mar 2016 

OncoTherapy Science Inc:Announces positive trial result of phase I clinical study of MELK inhibitor OTS167 in Australia.Says the clinical study turns out good oral absorption properties of OTS167.  Full Article

OncoTherapy Science announces completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’
Sunday, 21 Feb 2016 

OncoTherapy Science Inc:Says the phase I clinical study of the anti-cancer therapeutic antibody against synovial sarcoma ‘OTSA101’ has been completed.  Full Article

BRIEF-OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL

* Says peptide vaccine related agreement with ONO PHARMACEUTICAL CO., LTD. will close on Sept. 4